NZ742447A - Non-human animals having a humanized lymphocyte-activation gene 3 - Google Patents

Non-human animals having a humanized lymphocyte-activation gene 3

Info

Publication number
NZ742447A
NZ742447A NZ742447A NZ74244716A NZ742447A NZ 742447 A NZ742447 A NZ 742447A NZ 742447 A NZ742447 A NZ 742447A NZ 74244716 A NZ74244716 A NZ 74244716A NZ 742447 A NZ742447 A NZ 742447A
Authority
NZ
New Zealand
Prior art keywords
lag
rodent
humanized
polypeptide
gene
Prior art date
Application number
NZ742447A
Other languages
English (en)
Inventor
Andrew J Murphy
Elena Burova
Alexander O Mujica
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of NZ742447A publication Critical patent/NZ742447A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2517/00—Cells related to new breeds of animals
    • C12N2517/02—Cells from transgenic animals

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Environmental Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Public Health (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
NZ742447A 2015-11-20 2016-11-18 Non-human animals having a humanized lymphocyte-activation gene 3 NZ742447A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562258181P 2015-11-20 2015-11-20
US201662370430P 2016-08-03 2016-08-03
PCT/US2016/062733 WO2017087780A1 (en) 2015-11-20 2016-11-18 Non-human animals having a humanized lymphocyte-activation gene 3

Publications (1)

Publication Number Publication Date
NZ742447A true NZ742447A (en) 2022-12-23

Family

ID=57543170

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ742447A NZ742447A (en) 2015-11-20 2016-11-18 Non-human animals having a humanized lymphocyte-activation gene 3

Country Status (26)

Country Link
US (4) US10306874B2 (enExample)
EP (1) EP3376857B1 (enExample)
JP (1) JP6997708B2 (enExample)
KR (1) KR102454546B1 (enExample)
CN (1) CN108366548B (enExample)
AU (1) AU2016358101B2 (enExample)
BR (1) BR112018010158A2 (enExample)
CA (1) CA3003786C (enExample)
CY (1) CY1124171T1 (enExample)
DK (1) DK3376857T3 (enExample)
ES (1) ES2872799T3 (enExample)
HR (1) HRP20210824T1 (enExample)
HU (1) HUE054612T2 (enExample)
IL (1) IL258841B (enExample)
LT (1) LT3376857T (enExample)
MX (1) MX2018005389A (enExample)
NZ (1) NZ742447A (enExample)
PL (1) PL3376857T3 (enExample)
PT (1) PT3376857T (enExample)
RS (1) RS61866B1 (enExample)
RU (1) RU2745403C2 (enExample)
SG (1) SG11201803409UA (enExample)
SI (1) SI3376857T1 (enExample)
SM (1) SMT202100299T1 (enExample)
WO (1) WO2017087780A1 (enExample)
ZA (1) ZA201802717B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2841353T3 (es) 2014-12-09 2021-07-08 Regeneron Pharma Animales no humanos que tienen un gen del grupo de diferenciación 274 humanizado
HUE054612T2 (hu) 2015-11-20 2021-09-28 Regeneron Pharma Humanizált limfocitaaktiváló gén 3-t tartalmazó nem-humán állatok
SG10202001578RA (en) 2016-02-29 2020-04-29 Regeneron Pharma Rodents having a humanized tmprss gene
DK3476865T5 (da) 2016-06-28 2024-09-09 Biocytogen Pharmaceuticals Beijing Co Ltd Fremgangsmåde til konstruktion af pd-1-gen-modificeret humaniseret dyremodel og anvendelse deraf
CN107815468B (zh) 2016-08-31 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化基因改造动物模型的制备方法及应用
CN108070613B (zh) 2016-11-11 2020-03-13 百奥赛图江苏基因生物技术有限公司 人源化基因改造动物模型的制备方法及应用
WO2018086583A1 (en) * 2016-11-11 2018-05-17 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric lag-3
WO2019006034A1 (en) 2017-06-27 2019-01-03 Regeneron Pharmaceuticals, Inc. NON-HUMAN ANIMALS COMPRISING A HUMANIZED ASGR1 LOCUS
EP3585159B1 (en) 2017-07-31 2025-05-14 Regeneron Pharmaceuticals, Inc. Method of testing the ability of a crispr/cas9 nuclease to modify a target genomic locus in vivo, by making use of a cas-transgenic mouse or rat which comprises a cas9 expression cassette in its genome
MX2020001177A (es) 2017-07-31 2020-09-25 Regeneron Pharma Animales no humanos reporteros de crispr y usos de los mismos.
CA3071712C (en) 2017-09-29 2023-02-14 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ttr locus and methods of use
WO2019072241A1 (en) * 2017-10-13 2019-04-18 Beijing Biocytogen Co., Ltd NON-HUMAN ANIMAL GENETICALLY MODIFIED WITH PD-1 HUMAN OR CHIMERIC
CN109666701B (zh) * 2017-10-13 2021-08-24 百奥赛图(北京)医药科技股份有限公司 一种pd-1基因修饰人源化动物模型的构建方法及其应用
US11419318B2 (en) * 2017-11-30 2022-08-23 Regeneran Pharmaceuticals, Inc. Genetically modified rat comprising a humanized TRKB locus
AU2019239880B2 (en) 2018-03-19 2023-11-30 Regeneron Pharmaceuticals, Inc. Transcription modulation in animals using CRISPR/Cas systems
JP7328243B2 (ja) 2018-03-26 2023-08-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 治療薬を試験するためのヒト化げっ歯類
SG11202011284RA (en) 2018-07-16 2020-12-30 Regeneron Pharma Non-human animal models of ditra disease and uses thereof
WO2020125763A1 (en) * 2018-12-20 2020-06-25 Biocytogen Jiangsu Co., Ltd. Genetically modified non-human animal with human or chimeric lag3
CN109929875B (zh) * 2019-03-12 2021-02-19 江苏集萃药康生物科技股份有限公司 一种lag3基因人源化动物模型的构建方法及其应用
CN117178959A (zh) 2019-04-04 2023-12-08 瑞泽恩制药公司 包括人源化凝血因子12基因座的非人动物
JP7610339B2 (ja) 2019-06-04 2025-01-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ベータスリップ変異を有するヒト化ｔｔｒ遺伝子座を含む非ヒト動物と使用方法
BR112021022722A2 (pt) 2019-06-07 2022-01-04 Regeneron Pharma Animal não humano, célula de animal não humana, genoma de animal não humano, gene de albumina animal não humana humanizada, vetor de alvejamento, método de avaliação da atividade de um reagente, e, método de otimização da atividade de um reagente
KR20220133248A (ko) 2020-01-28 2022-10-04 리제너론 파마슈티칼스 인코포레이티드 인간화 pnpla3 좌위를 포함하는 비-인간 동물 및 사용 방법
CA3167557A1 (en) * 2020-04-21 2021-10-28 Davor Frleta Non-human animals having a humanized cxcl13 gene
WO2025163140A1 (en) * 2024-02-02 2025-08-07 Vacara Ab Physiologic humanized mice for studies of mhc class ii function

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0758383T3 (da) * 1994-05-06 2007-05-29 Roussy Inst Gustave Oplöselige polypeptidfraktioner af LAG-3-proteinet; fremgangsmåde til fremstilling; terapeutisk sammensætning; antiidiotypisk antistof
US5670356A (en) 1994-12-12 1997-09-23 Promega Corporation Modified luciferase
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
SI1897548T2 (sl) * 2003-02-28 2024-09-30 The Johns Hopkins University Regulacija celic T
ES2667169T3 (es) 2004-10-19 2018-05-09 Regeneron Pharmaceuticals, Inc. Método para generar un animal no humano homocigótico para una modificación genética
AR072999A1 (es) * 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
US8518392B2 (en) 2009-08-14 2013-08-27 Regeneron Pharmaceuticals, Inc. Promoter-regulated differentiation-dependent self-deleting cassette
ES2700852T3 (es) 2009-10-06 2019-02-19 Regeneron Pharma Ratones modificados genéticamente e injerto
US20130061340A1 (en) * 2011-09-02 2013-03-07 Stem Centrx, Inc. Identification and Enrichment of Cell Subpopulations
CN105861553B (zh) 2011-02-15 2020-08-14 再生元制药公司 人源化m-csf小鼠
HUE035652T2 (en) 2011-10-28 2018-05-28 Regeneron Pharma Genetically modified major histocompatibility complex mice
DK2663575T3 (en) 2011-10-28 2014-12-15 Regeneron Pharma HUMANIZED IL-6 and IL-6 receptor
LT2771357T (lt) * 2011-10-28 2018-10-25 Regeneron Pharmaceuticals, Inc. Pelės su genetiškai modifikuotu t ląstelių receptoriumi
KR102113108B1 (ko) 2011-10-28 2020-05-20 리제너론 파아마슈티컬스, 인크. 키메라 주요 조직적합성 복합체 （ｍｈｃ） 제ｉｉ부류 분자들을 발현하는 유전자전이 마우스
AR091649A1 (es) * 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
IL307969B1 (en) 2012-09-07 2025-10-01 Regeneron Pharma Genetically modified non-human animals and methods of using them
ES2773921T3 (es) * 2012-09-17 2020-07-15 Galectin Therapeutics Inc Método para mejorar las inmunoterapias específicas en el tratamiento del cáncer
CA2887706C (en) 2012-11-05 2022-08-02 Regeneron Pharmaceuticals Genetically modified non-human animals and methods of use thereof
WO2014130671A1 (en) 2013-02-20 2014-08-28 Regeneron Pharmaceuticals, Inc. Mice expressing humanized t-cell co-receptors
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
KR102211267B1 (ko) 2013-02-22 2021-02-04 리제너론 파아마슈티컬스, 인크. 사람화된 주요 조직적합성 복합체를 발현하는 마우스
SI2986729T1 (sl) 2013-04-16 2019-02-28 Regeneron Pharmaceuticals, Inc. Ciljana sprememba genoma podgane
RU2018136614A (ru) 2013-09-23 2018-11-27 Регенерон Фармасьютикалс, Инк. Отличные от человека животные с гуманизированным геном сигнального регуляторного белка
EP3071024B1 (en) 2013-11-19 2018-09-05 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized b-cell activating factor gene
ES2794942T3 (es) 2014-04-08 2020-11-19 Regeneron Pharma Animales no humanos que tienen receptores Fc-gamma humanizados
NO2785538T3 (enExample) 2014-05-07 2018-08-04
DK3145307T3 (en) 2014-05-19 2019-04-15 Regeneron Pharma RE-MODIFIED NON-HUMAN ANIMALS EXPRESSING HUMAN EPO
SG11201609638RA (en) 2014-06-19 2016-12-29 Regeneron Pharma Non-human animals having a humanized programmed cell death 1 gene
PL3223605T3 (pl) 2014-11-24 2021-04-19 Regeneron Pharmaceuticals, Inc. Zwierzęta inne niż ludzie eksprymujące humanizowany kompleks CD3
DK3466255T3 (da) 2014-12-05 2021-05-03 Regeneron Pharma Ikke-humane dyr med en humaniseret klynge af differentiering af 47-gen
ES2841353T3 (es) 2014-12-09 2021-07-08 Regeneron Pharma Animales no humanos que tienen un gen del grupo de diferenciación 274 humanizado
AU2016246698B2 (en) 2015-04-06 2022-06-02 Regeneron Pharmaceuticals, Inc. Humanized T cell mediated immune responses in non-human animals
HUE054612T2 (hu) 2015-11-20 2021-09-28 Regeneron Pharma Humanizált limfocitaaktiváló gén 3-t tartalmazó nem-humán állatok

Also Published As

Publication number Publication date
US11102961B2 (en) 2021-08-31
SG11201803409UA (en) 2018-05-30
CN108366548B (zh) 2021-10-08
AU2016358101A1 (en) 2018-05-31
SMT202100299T1 (it) 2021-07-12
US12096754B2 (en) 2024-09-24
US20210360908A1 (en) 2021-11-25
KR20180083381A (ko) 2018-07-20
ES2872799T3 (es) 2021-11-02
RU2018117944A3 (enExample) 2020-04-06
MX2018005389A (es) 2018-09-05
US20190320632A1 (en) 2019-10-24
CA3003786C (en) 2023-09-12
PT3376857T (pt) 2021-05-27
CA3003786A1 (en) 2017-05-26
CN108366548A (zh) 2018-08-03
SI3376857T1 (sl) 2021-09-30
US20170142943A1 (en) 2017-05-25
PL3376857T3 (pl) 2021-09-13
HUE054612T2 (hu) 2021-09-28
HK1253683A1 (en) 2019-06-28
CY1124171T1 (el) 2022-05-27
IL258841A (en) 2018-06-28
US20240397919A1 (en) 2024-12-05
JP2018533963A (ja) 2018-11-22
BR112018010158A2 (pt) 2018-11-21
RS61866B1 (sr) 2021-06-30
DK3376857T3 (da) 2021-05-25
KR102454546B1 (ko) 2022-10-14
US10306874B2 (en) 2019-06-04
WO2017087780A1 (en) 2017-05-26
RU2745403C2 (ru) 2021-03-24
JP6997708B2 (ja) 2022-02-04
HRP20210824T1 (hr) 2021-07-09
ZA201802717B (en) 2023-05-31
EP3376857A1 (en) 2018-09-26
IL258841B (en) 2021-04-29
LT3376857T (lt) 2021-06-25
EP3376857B1 (en) 2021-02-24
RU2018117944A (ru) 2019-12-20
AU2016358101B2 (en) 2022-12-01

Similar Documents

Publication Publication Date Title
NZ742447A (en) Non-human animals having a humanized lymphocyte-activation gene 3
Lommel et al. Protein O-mannosylation is crucial for E-cadherin–mediated cell adhesion
US12077592B2 (en) GPRC5D chimeric antigen receptors and cells expressing the same
Zhao et al. Female-to-male sex reversal in mice caused by transgenic overexpression of Dmrt1
Vagin et al. The Na-K-ATPase α1β1 heterodimer as a cell adhesion molecule in epithelia
Li et al. The implication and significance of beta 2 microglobulin: a conservative multifunctional regulator
Suemizu et al. A basolateral sorting motif in the MICA cytoplasmic tail
Barclay et al. The interaction between signal regulatory protein alpha (SIRPα) and CD47: structure, function, and therapeutic target
Tunquist et al. Loss of AKAP150 perturbs distinct neuronal processes in mice
Moody et al. Developmentally regulated glycosylation of the CD8αβ coreceptor stalk modulates ligand binding
Li et al. Structure of natural killer cell receptor KLRG1 bound to E-cadherin reveals basis for MHC-independent missing self recognition
Pasch et al. The LINC complex component Sun4 plays a crucial role in sperm head formation and fertility
East et al. A targeted deletion in the endocytic receptor gene Endo180 results in a defect in collagen uptake
Rossi et al. Clustering of pre-B cell integrins induces galectin-1-dependent pre-B cell receptor relocalization and activation
Horn et al. N-cadherin provides a cis and trans ligand for astrotactin that functions in glial-guided neuronal migration
JP2017513478A5 (enExample)
Lindenmaier et al. Dystroglycan is a scaffold for extracellular axon guidance decisions
FI3808775T3 (fi) Ei-ihmiseläimiä, joilla on humanisoitu erilaistumisklusteri 274 -geeni
JP2018533963A5 (enExample)
Hartmann et al. Elucidating different pattern of immunoregulation in BALB/c and C57BL/6 mice and their F1 progeny
JP2018500896A5 (enExample)
SA516380394B1 (ar) مستقبلات خلايا t لفيروس ورم حليمي 16 e7 مضادة للبشر
JP2018500012A5 (enExample)
RU2017105515A (ru) Сигнальная система
CN105612175A (zh) 基于IL-15和IL-15Rαsushi结构域的调节因子

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 NOV 2024 BY ANAQUA SERVICES

Effective date: 20231020

LAPS Patent lapsed